Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Phase 2
Not yet recruiting
- Conditions
- Biliary Tract Cancer (BTC)
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 74
- Registration Number
- NCT06919848
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Gastric AdenocarcinomaGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaPeritoneal Metastasis
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06914687
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06914674
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, China
TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC
Phase 2
Recruiting
- Conditions
- Endometrial Cancer
- Interventions
- Drug: TQB2450 injection + oral progestin
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06914297
- Locations
- 🇨🇳
Tenth People's Hospital of Tongji University, Shanghai, Shanghai, China
Neoadjuvant SNF Precision Therapy Phase III
Phase 3
Recruiting
- Conditions
- Neoadjuvant Therapy
- Interventions
- Drug: Chemotherapy (wP-EC)
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 404
- Registration Number
- NCT06913777
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
Not Applicable
Recruiting
- Conditions
- Breast CancerCytologySentinel Lymph NodeFrozen Section
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 709
- Registration Number
- NCT06911528
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases
Recruiting
- Conditions
- Colorectal CancerPeritoneal Metastases
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06903325
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Lung Atelectasis Improvement Through Positive End Expiratory Pressure During Anesthetic Induction
Not Applicable
Completed
- Conditions
- Lung Injury, Acute
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT06900426
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Centre, Shanghai, Shanghai, China
An Observational Study for Gastric Cancer in Asymptomatic Carriers of High Risk Helicobacter Pylori
Not yet recruiting
- Conditions
- Gastric (Stomach) CancerHelicobacter Infection
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 6000
- Registration Number
- NCT06896370
The Efficacy and Safety of Narlumosbart in Combination with Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined with Immunotherapy in Patients with Bone Metastases from Advanced Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- NSCLCStereotactic Body Radiation Therapy (SBRT)Immunotherapy
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 27
- Registration Number
- NCT06738160